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In a high-resolution MALDI-TOF mass spectrum, a peptide produces multiple peaks, corresponding to the isotopic variants of
the molecules. An overlap occurs when two peptides appear in the vicinity of the mass coordinate, resulting in the diﬃculty
of quantifying the relative abundance and the exact masses of these peptides. To address the problem, two factors need to be
considered: (1) the variability pertaining to the abundances of the isotopic variants (2) extra information content needed to
supplement the information contained in data. We propose a Bayesian model for the incorporation of prior information. Such
information exists, for example, for the distribution of the masses of peptides and the abundances of the isotopic variants. The
model we develop allows for the correct estimation of the parameters of interest. The validity of the modeling approach is veriﬁed
by a real-life case study from a controlled mass spectrometry experiment and by a simulation study.
1.Introduction
Peptide-centric techniques are gaining a lot of interest for
the search of new protein biomarkers, surrogate endpoints,
or markers for classiﬁcation of diseases. Typically, such
t e c h n i q u e se x t e n s i v e l yu s em a s ss p e c t r o m e t r y( M S )f o r
protein-expressionproﬁling,becausetheypromotethehigh-
throughput quantitative characterization of a proteome. MS
allows to separate peptides, present in a sample, according to
their masses. It also provides a measure of abundance of the
peptides. By comparing the protein abundances for diﬀerent
samples, diﬀerentially expressed proteins can be found. By
analyzing the proteins, important information about, for
example, mechanisms of disease can be obtained.
In this paper, we consider the problem of the quan-
tiﬁcation of overlapping peptides in a high-resolution
matrix-assisted laser desorption and ionisation/time-of-
ﬂight (MALDI-TOF) mass spectrum (MS).
Peptides are chains of amino acids and are composed
of atoms of ﬁve chemical elements: carbon (C), hydrogen
(H), nitrogen (N), oxygen (O), and sulphur (S). Because the
chemical elements have diﬀerent isotopes, peptides can have
diﬀerent isotopic variants, which diﬀer with respect to their
weights. For a peptide of a known chemical composition,
the probability of occurrence of these variants is called
the isotopic distribution. It follows that, in a singly charged
high-resolution mass spectrum, a peptide produces a series
ofpeaksthatareseparatedbyonemassunit(dalton,Da)and
that correspond to diﬀerent isotopic variants of the peptide.
These peaks are called isotopic peaks. Their relative heights
pertain to the probabilities of the isotopic distribution of the
peptide.
A “cluster” of peaks observed in a mass spectrum can
be produced by more than one peptide. This happens if two
peptides diﬀer in mass by at most a few mass units. Such
peptides are called overlapping peptides. Figure 1 illustrates2 International Journal of Proteomics
a possible scenario for the case of no measurement noise. It
shows, in Figure 1(a), isotopic peaks for three overlapping
peptides. The resulting observed joint spectrum is presented
in Figure 1(b), with a “cluster” of superimposed peptide
peaks. Our key interest is to quantify the true underlying
peptides, as displayed in Figure 1(a). The quantiﬁcation
means a proper assessment of (1) the number of overlapping
peptides (components), (2) the monoisotopic masses of the
peptides, that is, the masses of the isotopic variants that
contain the most abundant isotopes of chemical elements
constructing the peptides, and (3) the corresponding
abundances of the peptides.
Several approaches to the problem of quantiﬁcation of
overlapping peptides have been proposed. Schulz-Trieglaﬀ
et al. [1] and Lange et al. [2] developed a peak-picking
algorithm by means of a wavelet function, combined with
a greedy search to quantify the overlapping peptides. This
method has two limitations: (1) often no unique solution
can be found for the wavelet functions to ﬁt to the peptide
proﬁles, and (2) greedy search is often problematic in
that it can either include noise peaks as peptide peaks or
discard peptide peaks, depending on the ﬁt to the wavelet
functions. These limitations acting together can lead to
nonidentiﬁcation or misidentiﬁcation of the overlapping
peptides. Breen et al. [3] suggested to model the isotopic
distribution by a Poisson approximation, which can also
be used to identify overlapping peptides. The method is
based on the summary statistics of the original data. This
limits the application of the method, for example, by not
allowing for the estimation of the mass locations of these
peptides. Moreover, the use of the summary statistics could
result in severe ineﬃciency of the parameter estimates. Espe-
cially when there is discrepancy between the true isotopic
distribution and the Poisson-approximated one, it would
incur biased quantiﬁcation for the parameters of interest, for
example, the relative abundance(s) of these peptides.
The quantiﬁcation of the overlapping peptides is a diﬃ-
cult problem, because the data may contain a very limited
amount of information that can be used to distinguish
between diﬀerent conﬁgurations of the number, location,
and abundances of the peptides, which might have led to the
observed joint spectrum. A possible solution is to use prior
information that could increase the information content of
the data. To this aim, in the paper we propose to use a
Bayesian model to analyze high-resolution mass spectra with
overlapping peptides. The model allows to use the prior
information about, for example, the possible location of the
peptidesandabouttheirisotopicdistribution.Itisimportant
to note that the prior information reﬂects a prior knowledge
that can be helpful in analyzing the data but does not neces-
sarily need to exactly represent the data. In other words, the
prior and the data can come from diﬀerent types of proteins.
This is because, in the Bayesian framework, the posterior
is (combined) information of the prior and the data, being
closer to the source that contains more information.
Our paper is organized as follows. Section 2 presents the
shape representation of the MS data that we will consider for
our modeling. In Section 3, we discuss the prior information
that can be used in analyzing MS data with overlapping
peptides. The details of the Bayesian modeling approach are
formulated in Section 4.I nSection 5, results of an analysis
of real-life data sets and a simulation study are presented.
Finally, concluding remarks are given in Section 6.
2. Shape Representationof aMass Spectrum
For the data representation, used for the modeling approach,
one way is to base the analysis on the summarized informa-
tionoftheMSdataby,forexample,usingonlyonedatapoint
representing one observed peak. In principle, this implies a
severe information reduction and may consequently cause
biased estimation. In order to avoid the problem and retain
all the information from the data, we consider the original
setting of the MS data by means of the (peak-)shape
representation.
To work with the shape representation, all mass coor-
dinates and their corresponding intensities are considered.
Assume that, for a peak cluster observed in a mass spec-
trum, as shown in Figure 1(b),w eh a v eg o tN intensity
measurements, denoted by yj (j = 1,...,N), and obtained
at masses xj. The intensity at mass coordinate xj is a
sum of intensity measurements of all the isotopic peaks
of the peptides that are present at that coordinate. Thus,
for the example shown in Figure 1, yj = h1ψ(xj;μ1,σ2
s )+
h2ψ(xj;μ2,σ2
s )+h3ψ(xj;μ3,σ2
s ), where ψ(x;μ,σ2
s )i sas u i t -
able function capturing the shape of the peak envelope like,
for example, the normal function (either cdf or pdf) with μq
and hq denoting, respectively, a mass location and an overall
abundance parameter for the qth overlapping peptide, and
σs, a dispersion parameter.
The shape representation uses the full content of the MS
data and therefore, in principle, allows for a more eﬃcient
inference.
3. Available Prior Information
As mentioned in Section 1, the use of prior information
could increase the information content of the MS data
and allow for a more eﬃcient quantiﬁcation of overlapping
peptides. Such information is indeed available.
3.1. Prior Information for Monoisotopic Mass. The RefSeq
database of the NCBI, available at http://www.ncbi.nlm.nih
.gov/RefSeq/, provides the monoisotopic masses of human
peptides. When accessed on February 27, 2008, for the
human proteome, the database contained amino acid
sequences for 132,292 proteins. Performing an in silico digest
bytrypsineresultedin2,616,371peptideswithmonoisotopic
masses between 400 and 4000Da, with 306,427 unique
atomic compositions. Figure 2 presents the number of pep-
tides with monoisotopic masses appearing in small intervals
of 0.01Da around the mass range of 2000Da. It can be
observed that the monoisotopic masses vary around integer
values. Moreover, there are regions where no peptides can
be found. This prior information can be quantiﬁed by
using an appropriate prior distribution in modelling MS
data.International Journal of Proteomics 3
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Figure 1: The observed spectrum (b) and its corresponding true underlying peptide components (a).
Table 1: The polynomial model coeﬃcient estimates.
logC2 logC3 logC4 logC5 logC6 logC7 logC8
β0 −2.5835 −2.6283 −2.9429 −3.1161 −3.2939 −3.4508 −3.6021
β1 3.2954 2.3416 2.4265 2.3733 2.4299 2.4994 2.5967
β2 −1.7098 −1.0856 −1.2003 −1.1854 −1.2464 −1.3110 −1.3932
β3 0.4594 0.2772 0.3197 0.3176 0.3386 0.3600 0.3865
β4 −0.0466 −0.0274 −0.0324 −0.0323 −0.0347 −0.0372 −0.0401
σ2 0.0035 0.0008 0.0006 0.0010 0.0012 0.0016 0.0019
3.2.PriorInformationfortheIsotopicDistribution. TheNCBI
data can also be used to extract information about possible
forms of the isotopic distribution of peptides. Note that,
to compute the isotopic distribution, information about
the chemical composition of the peptide is needed. Such
information is not available in a mass spectrum. However,
onecanpredictthedistributionbyconsideringthevariability
of the distribution of peptides with a similar monoisotopic
mass.
To this aim, the isotopic distribution can be modeled by
using a polynomial model, with the monoisotopic mass as a
covariate [4, 5]. Valkenborg et al. [5] suggested that a fourth-
order polynomial is suﬃcient for modeling purposes. The
model is applied to the isotopic ratios, which are deﬁned as
follows. Let p1, p2, p3, and so forth denote the probability
of occurrence of, respectively, the ﬁrst (monoisotopic),
second, third, and so forth (with respect to the increasing
mass), isotopic variant of a peptide, given by the isotopic
distribution. The common reference ratios are deﬁned as
follows: R1 = p1/p1 = 1, R2 = p2/p1, and so forth. Thus,
they give the probability of occurrence of an isotopic variant
relative to the probability of the monoisotopic variant. The
consecutive isotopic ratios a r ed e ﬁ n e da sf o l l o w s :C1 = p1/p1,
C2 = p2/p1, C3 = p3/p2, and so forth. Thus, they give
the probability of occurrence of an isotopic variant relative
to the previous variant. Note that the two sets of ratios are
equivalent, because Rl = C1C2 ···Cl.
We used the approach by ﬁtting the following model
to the logarithms of the consecutive ratios of the isotopic
distributions of peptides from the NCBI data set:
logCl =
4  
k=0
βk
 
m
1000
 k
+ε, (1)
where m is the monoisotopic mass of the peptide and ε ∼
N(0,σ2
l ). Model (1) was applied to the logarithms of ratios
Cl,andnottoratiosRl,becausetheassumptionsofthemodel
were more appropriate for the former set of ratios.
Theestimatedcoeﬃcientsofthemodelforisotopicratios
l = 2 to 8 are shown in Table 1. They allow to infer the form
of the isotopic distribution of a peptide with monoisotopic
mass m. Again, this prior information can be quantiﬁed by
using an appropriate prior distribution in modelling MS
data.4 International Journal of Proteomics
3.2.1. Reparameterization as A Virtual Constraint of the Iso-
topic Ratio Estimates. Due to the fact that Rl = C1C2 ···Cl,
theoverestimationofconsecutiveratioC1 wouldresultinthe
over-estimation of all the common reference ratios R1 to Rl.
To circumvent the problem, the ratios can be reparameter-
ized. Recall that pl is the probability of occurrence of the
lthe isotopic variant and thus
 L
i=1 pl = 1, where L is the
total number of isotopic variants, observed for a peptide. As
Rl = pl/p1, we then have
R2 =
L  
l=2
Rl −
L  
l=3
Rl =
1 − p1
p1
−
L  
l=3
Rl. (2)
Hence, instead of putting a prior on R2, we use the equality
relationship in (2) and deﬁne a prior for (1 − p1)/p1.
The reparameterization becomes a virtual constraint for the
common-reference ratios. This is because the increase of the
other ratios, as shown in (2), would result in the shrinkage of
R2 (given p1).
The prior for (1− p1)/p1 was obtained by ﬁtting a model
with monoisotopic mass m as a covariate to the isotopic
distributions of the NCBI data set. A linear relationship
between the logarithm of p1 and m, which can be expressed
as p1 = α + βm + ε, was found. It can then be transformed
to the log-odds scale of p1. After the transformation, the
residuals were observed to be more homoscedastic. Thus, the
model takes the form
log
 
1 − p1
p1
 
= log
 
1 −exp
 
α+βm
  
−
 
α+βm
 
+ε,
(3)
where ε ∼ N(0,σ2
p1). The resulting prior for the common-
reference (isotopic) ratio Rlq is lognormal, that is,
Rlq ∼ Log-normal
⎛
⎝
l  
i=1
μi,
l  
i=1
σ2
i
⎞
⎠,
where l = 3,...,L,
(4)
and R2q = (1 − p1)/p1 −
 L
l=3Rlq.T h ep r i o rf o r( 1− p1)/p1
can be obtained from the estimates of the model shown in
(3). More speciﬁcally,
 
1 − p1
 
p1
∼ Log-normal
 
μp1,σ2
p1
 
,
where μp1 = log
 
1 −exp
 
α+βm
  
−
 
α+βm
 
.
(5)
4. Bayesian Model Formulation
In this section, we consider a model for the peak-shape
representation of a mass spectrum.
4.1. Model Formulation. We assume that the number of the
overlapping peptides, Q, is known. Essentially, the model
formulation is based on the deﬁnition in Section 2.F o r
the observed intensity yj (j = 1,...,N), we assume the
following model:
yj ∼ N
 
E
 
yj
 
,σ2
 
,( 6 )
with
E
 
yj
 
= f
 
H,R,M,σ2
s ,S
 
=
Q  
q=1
L  
l=1
HqRlqψ
 
xj;Mq +(l −1)S,σ2
s
 
,
(7)
where xj is the mass coordinate corresponding to intensity
yj, M = (M1,M1,...,MQ) is a vector of monoisotopic
masses of the Q overlapping peptides, and S is the diﬀerence
in mass locations between two neighboring isotopic peaks
of the same peptide, assumed to be constant over all
the isotopic peaks for all the overlapping peptides. In
(7), Hq is the abundance of the qth overlapping peptide
(q = 1,2,...,Q)a n dH = (H1,...,HQ). Parameter Rlq is the
lth common reference isotopic ratio for the qth peptide, and
R = (R11,R21,...,RL1; R12,R22,...,RL2;...;R1Q,R2Q,...,RLQ)
is a vector containing the isotopic ratios for all peptides. The
function ψ(x;μ,σ2
s ) is a function of a chosen distribution,
deﬁned for the shape of the peaks. In this respect,
either the diﬀerence of a cdf (cumulative distribution
function) between two neighboring mass coordinates or
a pdf (probability distribution function) can be used. To
approximate the (underlying) continuous mass coordinate,
we chose to use the cdf, which is also believed to be a more
accurate approximation of area under the curve especially
when the dispersion parameter σs takes very small values.
For a normal distribution function, the area under the curve
between two neighboring mass coordinates is
ψ
 
xj;Mq +(l −1)S,σ2
s
 
=
⎧
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎩
Φ
 
xj | Mq+(l−1)S,σ2
s
 
−Φ
 
xj−1 | Mq+(l−1)S,σ2
s
 
if j ≥ 2,
Φ
 
xj | Mq+(l−1)S,σ2
s
 
−Φ
 
0 | Mq+(l−1) S,σ2
s
 
if j = 1,
(8)
with Φ(xj | Mq +( l − 1)S,σ2
s ) denoting the value of the
normal cdf function with mean Mq +( l − 1)S and variance
σ2
s , calculated at xj.
Peaks in MS data often exhibit a right-skewed shape.
Thus, an alternative is to approximate the shape by a
functionthataccountsforanasymmetricshape.Asymmetric
Laplace function can serve for this purpose. In this case, an
extra shape parameter—the skewness parameter κ—shouldInternational Journal of Proteomics 5
be included. The shape function takes the following
form:
ψ
 
xj;Mq +(l −1)S,σs,κ
 
=
⎧
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎩
F
 
xj | Mq +(l −1)S,σs,κ
 
−F
 
xj−1 | Mq +(l −1)S,σs,κ
 
if j ≥ 2,
F
 
xj | Mq +(l −1) S,σs,κ
 
−F
 
0 | Mq +(l −1)S,σs,κ
 
if j = 1,
(9)
with F(xj | Mq +( l − 1)S,σs,κ) denoting the value of cdf
function of an asymmetric Laplace distribution with mean
Mq +(l−1)S and standard deviation σs, calculated at xj, that
is,
F
 
xj | Mq +(l −1) S,σs,κ
 
=
⎧
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎪ ⎩
κ2
1+κ2 exp
 
−
√
2
σsκ
     xj −
 
Mq +(l −1)S
      
 
if xj <M q +(l −1)S,
1 −
1
1+κ2 exp
 
−
√
2κ
σs
     xj −
 
Mq +(l −1)S
      
 
if xj ≥ Mq +(l − 1)S.
(10)
4.2. Prior Distributions. For Hq, σ2, σs, S,a n dκ, we use the
following noninformative or weak-informative priors:
Hq ∼ N
 
0,
1
τ
 
I
 
Hq ≥ 0
 
with τ ∼ Γ
 
α
∗,β
∗ 
,
σ−2 ∼ Γ
 
α,β
 
,
σs ∼ N
 
0,106 
I (0 ≤ σs ≤ 0.5),
S ∼ N
 
1,
1
τs
 
with τs ∼ Γ
 
α∗∗,β∗∗ 
I (τs ≥ 1600),
κ ∼ U(0.01,0.99),
(11)
where α, β, α∗, β∗, α∗∗,a n dβ∗∗ are positive constants close
to zero. To avoid numerical problems, Hq isconstrainedtobe
nonnegative. The peak-width parameter σs is constrained to
be positive and not larger than 0.5, because peaks observed
in a spectrum are clearly separated from each other, with the
width of a peak not larger than 1Da. Parameter S reﬂects the
average diﬀerence in molecular weight of the isotopes and is
usually very close to one. Thus, S is constrained to be close
to one by setting a lower bound for the precision parameter
τs. The skewness parameter κ (for the asymmetric Laplace
function)isconstrainedtobesmallerthanonesincethepeak
envelopsarealwaysrightskewed(atleastintheMALDI-TOF
data).
The informative priors for the isotopic ratios are deﬁned
by (4)a n d( 5).
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Figure 2: Histogram of the monoisotopic mass locations of
peptides in the mass range of 1997.5–2002.5Da in the NCBI data
set.
4.2.1. Bayesian Model Averaging for the Estimation of
Monoisotopic Masses M. Figure 2 shows that monoisotopic
masses appear in “clusters” of bell shape. This suggests that
a suitable choice for the prior distribution of M, at a speciﬁc
“cluster” for the possible mass range of M,m a yb ean o r m a l
distribution. Thus, the prior for the monoisotopic mass of
the qth peptide is deﬁned as follows:
Mq ∼ N
 
ηg,σ2
m
 
, (12)
where g = 1,...,G,w i t hG being the number of “clusters,”
at which the monoisotopic masses are likely to occur. For
instance, assuming that the monoisotopic mass of a certain
peptide can vary in the mass range of [1997.5,2002.5]Da, as
shown in Figure 2, then G = 5, as there are ﬁve “clusters”
shown in the ﬁgure. Mean ηg and variance σ2
m can be
estimated from the NCBI data (as illustrated in Figure 3).
To consider all the G possible locations “clusters,” which
can possibly contain the true value of the monoisotopic
mass of the overlapping peptide, a Bayesian model averaging
approach can be considered. More speciﬁcally, G candidate
models are ﬁtted, each with a normal prior N(ηg,σ2
m),
and g = 1,...,G. The resulting parameter estimates are a
weightedsumoftheGcandidatemodels.Thismeansthatthe
point estimate of a parameter θ is obtained as the weighted
average of the model-speciﬁc estimates   θg
  θ =
G  
g=1
wg   θg, (13)
where wg is the weight of the gth model. Based on the DIC
(deviance information criterion) of each model, wg can be
computed as follows [6]:
wg =
exp
 
−(1/2)ΔDICg
 
  G
g=1 exp
 
(−1/2)ΔDICg
   , (14)6 International Journal of Proteomics
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Figure 3: Graphical demonstration of the estimation of mean ηg
and standard deviation σm for the prior normal density of Mq: ηg is
chosen to be the mode of the “cluster”; σmg is taken as a third of the
maximum of spread1( l e f ts p r e a d )a n dspread2 (right spread); σm
is deﬁned as the maximum value of σm1,...,σmG.
where ΔDICg = DICg −ming(DICg). The standard error can
be computed as [6, 7]
  σ(θ) =
G  
g=1
wg
 
  σg(θ)
2 +
 
  θg −   θ
 2
, (15)
where   θg and   σg(θ) are, respectively, the point estimate and
the standard error for parameter θ in the gth candidate
model.
4.3. Conditional Posterior Distributions. The conditional
posterior distributions of Hq and σ2 can be obtained
analytically. On the other hand, because of nonlinearity,
there are no analytical solutions for the conditional posterior
distributions for S, κ, σs, Mq,a n dRlq. These distributions
therefore need to be evaluated by numerical (sampling)
methods, for example, a Metropolis-Hasting algorithm with
acception-rejection rules.
5.Dataanalysis
To investigate the performance of the proposed modeling
approach, we applied the model to real-life and simulated
data. The model was ﬁtted by using the R package
R2WinBUGS,b u i l ti n R to automatically call the (Win-
BUGS1.4) software, which allows to ﬁt Bayesian models.
5.1. Bovine Cytochrome C Mass Spectra. The model was
applied to a data set of replicated joint mass spectra obtained
for peptides of bovine cytochrome C from LC Packings.
Bovine cytochrome C is a relatively small protein related to
mitochondria in a cell. It is a chain of 105 amino acids. A
peptidemixtureoftrypticdigestedbovinecytochromeCwas
purchased from LC Packings and mixed with ﬁve internal
standards from Laser BioLabs used for the calibration of
the mass spectrometer. According to the data sheets of the
suppliers, the mixture should contain 17 protein fragments.
The amino acid sequences and the theoretical monoisotopic
masses of these fragments are known.
The peptide mixture was divided into two parts. One
part was enzymatically labeled with a stable 18O-isotope,
with trypsine as a catalyst, while the other part remained
unlabeled[8].Intheﬁrstcase,threeunitsfromtheunlabeled
part were mixed with one unit from the labeled part,
which should result in the relative abundance of 1/3. In
the second case, three units from the labeled part were
mixed with one unit from the unlabeled part, what should
result in the relative abundance of 3/1. In both cases, the
composed mixture was automatically spotted six times on
one stainless steel plate by a robot. The plate was processed
by a 4800 MALDI-TOF/TOF analyzer (Applied Biosystems)
massspectrometerandyieldedsixspectraforthe1/3mixture
and six spectra for the 3/1m i x t u r e .
In the 18O labeling strategy, the labeled peptide ideally
receives two 18O-atoms at its carboxyl terminus, which leads
to a four-Da mass shift of the corresponding peptide peaks
when analyzed by a mass spectrometer [8]. Thus, each
spectrum can be treated as containing pairs (Q = 2) of
overlappingpeptideswiththediﬀerenceinthemonoisotopic
masses equal to four units of mass diﬀerence between two
neighboring isotopic peaks, that is, M2 = M1+4S = M1+4×
1.0015 (see the notation of Section 4).
For the analysis purposes, we chose two peptides with
monoisotopic masses of 1456.66Da and 1584.76Da. For
each peptide, we considered one spectrum for each of two
diﬀerent relative abundances (1/3 or 3/1) of the 16Oa n d18O
labeledpeptides.Thisresultsinthefollowingfour(sub-)data
sets:
Data 1: M1 = 1456.66248, H2/H1 = 3/1,
Data 2: M1 = 1456.66248, H2/H1 = 1/3,
Data 3: M1 = 1584.75744, H2/H1 = 3/1,
Data 4: M1 = 1584.75744, H2/H1 = 1/3.
A graphical representation of data sets 1 and 2 is shown in
Figure 4.
5.1.1. Results of the Model Fit. Tables 2 and 3 show the means
and the standard errors for the parameters of model (6)-
(7), based on 100,000 samples, for the four data sets, using
asymmetric Laplace function deﬁned by (9)-(10).
The parameters of main interest are
(i) the estimates of the monoisotopic masses of the two
overlapping peptides, M1 and M2;
(ii) the relative abundance H2/H1.
Note that, usually, instead of the relative abundance,
abundances H1 and H2 of the overlapping peptides would
be of interest. However, in the analyzed experiment, only
ratio H2/H1 was controlled. Thus, it is of interest to verify
whether the proposed models correctly estimate the relative
abundance.International Journal of Proteomics 7
0
5000
15000
I
o
n
c
o
u
n
t
s
1460 1465 1470
(Da)
(a) Data 1 (H2/H1 = 3/1)
0
5000
15000
I
o
n
c
o
u
n
t
s
1460 1465 1470
(Da)
(b) Data 2 (H2/H1 = 1/3)
Figure 4: Graphical representation of the ﬁrst and the second data sets.
Table 2: Means and standard errors based on model averaging for the parameters of the model with asymmetric Laplace shape function.
Parameter Data set 1 Data set 3
True Mean S.E. True Mean S.E.
R21 0.7933 0.7615 0.01930 0.8703 0.8419 0.01850
R31 0.3567 0.4357 0.01472 0.4223 0.5305 0.01507
R41 0.1166 0.1536 0.009825 0.1478 0.1973 0.01213
R51 0.0306 0.0324 0.002528 0.0413 0.0431 0.003362
M
∗
1 1456.66 1456.668 0.0012 1584.76 1584.762 0.0007
R22 0.7933 0.7717 0.008791 0.8703 0.8571 0.008971
R32 0.3567 0.3362 0.006908 0.4223 0.4057 0.007161
R42 0.1166 0.1104 0.005162 0.1478 0.1417 0.005569
R52 0.0306 0.0315 0.002299 0.0413 0.0419 0.002860
M
∗
2 1460.67 1460.676 0.0009 1588.77 1588.771 0.0005
σ — 232.6181 6.6199 — 217.1335 6.5086
σs — 0.0734 0.0007 — 0.0770 0.0007
κ — 0.8637 0.01402 — 0.8095 0.007834
S — 1.0018 0.0006 — 1.0029 0.0004
H2/H1 2.4 2.2519 0.03791 2.4 2.2181 0.03462
Inthisrespect,itisimportanttomentionthat,despitethe
eﬀortstocontroltheexperiment,itappearsthat,fordatasets
1 and 3, the achieved value of relative abundance H2/H1 was
about 2.4, not 3. The value was estimated by using models
for the analysis of 18O-labeled mass spectra [9, 10]. This
value was therefore assumed as a true relative abundance in
Table 2.
S e v e r a lp a t t e r n sc a nb eo b s e r v e df r o mT a b l e s2 and 3.
First, for all of the data sets, the monoisotopic mass of the
second peptide M2 is estimated at the correct peak 5th peak.
The monoisotopic mass of the ﬁrst peptide M1 is estimated
with a negligible bias.
The point estimates of the relative abundance H2/H1
are slightly biased downwards. This may be due to the
fact that in experiments, in which 18O-labeling is used, a
part of peptide molecules from a labeled sample do not
get a complete label [9, 10]. These incompletely labeled
molecules additionally overlap with the molecules from the
unlabeled sample. This, in eﬀect, leads to the labeled sample
appearing in the spectrum to be less abundant due to the
amount of molecules that were incompletely labeled. Thus,
the downward bias observed for the estimates of the relative
abundance in Tables 2 and 3 may actually reﬂect this eﬀect.
The point estimates for isotopic ratios R are, in general,
very close to the true values. Taking the precision measure
of the standard errors into account, the diﬀerences between
these ratio estimates and their true values are negligible. The
parameters that describe the shape of the peaks, that is, S, κ,8 International Journal of Proteomics
Table 3: Means and standard errors based on model averaging for the parameters of the model with asymmetric Laplace shape function.
Parameter Data set 2 Data set 4
True Mean S.E. True Mean S.E.
R21 0.7933 0.7907 0.008395 0.8703 0.8598 0.008567
R31 0.3567 0.3593 0.006669 0.4223 0.4347 0.006836
R41 0.1166 0.1229 0.005162 0.1478 0.1575 0.005743
R51 0.0306 0.0328 0.002562 0.0413 0.0441 0.003436
M
∗
1 1456.66 1456.674 0.0006 1584.76 1584.764 0.0006
R22 0.7933 0.7842 0.02669 0.8703 0.8487 0.02809
R32 0.3567 0.3508 0.01589 0.4223 0.4072 0.01712
R42 0.1166 0.1202 0.007787 0.1478 0.1493 0.009163
R52 0.0306 0.0322 0.002467 0.0413 0.0430 0.003287
M
∗
2 1460.67 1460.682 0.0011 1588.77 1588.773 0.0011
σ — 278.7780 7.7737 — 273.1138 7.8657
σs — 0.0742 0.0007 — 0.0767 0.0007
κ — 0.8662 0.01141 — 0.7591 0.008672
S — 1.0022 0.0006 — 1.0028 0.0005
H2/H1 1/3 0.3059 0.007047 1/3 0.3064 0.007222
Table 4: The combinations of parameters used for the 30 settings of the simulation study.
Set 1 Set 2 Set 3 Set 4 Set 5 Set 6 Set 7 Set 8
shift 00110011
tilt 0.04 0.04 0.04 0.04 0.16 0.16 0.16 0.16
H2/H1 0 . 250 . 250 . 520 . 52
Isotopic ratios E1E2 E1E2 AA AA E2A E2A AE1 AE1
Set 9 Set 10 Set 11 Set 12 Set 13 Set 14 Set 15 Set 16
shift 01000101
tilt 0.24 0.24 0.24 0.16 0.16 0.16 0.04 0.04
H2/H1 1 1 2 0.2 5 0.2 0.5 0.5
Isotopic ratios E2E1 E1E1 E2A E1E2 E1E2 AA E2A AE1
Set 17 Set 18 Set 19 Set 20 Set 21 Set 22 Set 23 Set 24
shift 10014466
tilt 0.04 0.04 0.16 0.04 0.04 0.04 0.04 0.04
H2/H1 2111 0 . 2 5 0 . 2 5
Isotopic ratios AE1 E2E1 E2E1 E1E1 AA AA E1E2 E1E2
Set 25 Set 26 Set 27 Set 28 Set 29 Set 30
shift 446646
tilt 0.16 0.16 0.16 0.16 0.24 0.24
H2/H1 0.5 2 0.5 2 1 1
Isotopic ratios AE1 AE1 E2A E2A E2E2 E2E1
and σs, are estimated consistently for diﬀerent data sets. This
indicates that the peak proﬁles, obtained from the MALDI-
TOF experiments, are very similar.
As a comparison, we apply one of the existing
approaches, proposed by Breen et al. [3], to the same data
sets. It should be noted that by applying this approach, based
on the summary statistics, that is, the stick representation
for each observed peak, the monoisotopic masses of the two
peptides are not estimable. Thus, we merely focus on the
comparison of the relative abundance parameter H2/H1.T h e
estimated 95% conﬁdence intervals for this parameter for
the four data sets are, respectively, (1.9229, 2.5406), (0.2797,
0.3469), (1.9206, 2.5261), and (0.2826, 0.3479). They show
severe eﬃciency loss (as the conﬁdence intervals are much
wider)comparedwiththeresultspresentedinTables2and3.
5.2. A Simulation Study. For illustration purposes and
simplicity, the simulation study was based on the model with
a normal-density shape function. We considered 30 settings,
accounting for various mass diﬀerences of the overlapping
peptides. The details of the settings are shown in Table 4.
Let shift be the integer of the mass diﬀerence of the twoInternational Journal of Proteomics 9
Table 5: Estimability for settings with various combinations of shift, tilt, and H2/H1. (+: correct estimation; −: wrong estimation).
RH 12 5
H2/H1 RH RH 1/RH RH 1/RH RH 1/RH RH 1/RH RH
shift 0 100110011
tilt =0.04 − + −−++−−−+
tilt =0.16 + + + − ++++++
tilt =0 . 2 4 + +++++++++
overlapping peptides, and let tilt be the mass diﬀerence after
the decimal point. As a result, the mass diﬀerence of the two
overlapping peptides is equal to M2 − M1 = shift + tilt, or
in other words, M2 = M1 + shift + tilt. It may be diﬃcult to
quantify two overlapping peptides when the mass diﬀerence
between two peptides is too small, that is, either shift or tilt
is very small. Thus, it is of interest to investigate diﬀerent
settings with combinations of the two parameters.
In the simulation, we chose three sets of isotopic ratios:
an average one (denoted by A), obtained by a Poisson
approximation proposed by Breen et al. [3]; the extremely
small ratios (denoted by E1); the extremely large ratios
(denoted by E2) within 20001 ± 0.5Da mass range. Sets E1
and E2aretheisotopicdistributionswiththesecondisotopic
variant, p2, being the least and most abundant among all the
peptides around 2001 Da from the NCBI data.
The other parameters were chosen as follows:
M1 = 2000.90, H1 = 10000,
σ = 10, σs = 0.08, S = 1.0015.
(16)
For each of the settings, 100 simulated data sets with random
noise were generated. Figures 5 and 6 show the graphical
representation of the 30 settings. It can be seen that settings
1–3, 5–7, 9–16, 18-19, and 21 are diﬃcult settings, for
which the location of the second overlapping peptide is not
immediately obvious. In these settings, either the second
(overlapping) peptide is much less abundant than the ﬁrst
peptide (e.g., setting 21), or the mass diﬀerence between the
two peptides is very small (e.g., setting 2).
The graphical representation of the summary statistics
for the important parameters is shown in Figures 7–9.
Figure 7 shows, in general, unbiased estimates for parameter
M1,e x c e p to n l yf o raf e wo ft h ed i ﬃcult settings, which
exhibit slight bias. The point estimates of the monoisotopic
mass for the second overlapping peptide M2, shown in
Figure 8, correctly represent the true mass of the peptide,
except only for settings 1–3, 6, 15, and 18. For these settings,
the 95% credible intervals, computed based on the model
averaging, are very wide. Thus, most of them still contain
the true values of M2. The wide credible intervals are an
indication of settings, for which the quantiﬁcation of the
overlapping peptides is diﬃcult. For these diﬃcult settings,
the 95% credible intervals for H2/H1, as shown in Figure 9,
contain zero and thus can be viewed as another indication
that the second overlapping peptide is diﬃcult to be found.
For the remaining settings, even for some of those, for which
the presence of the second peptide is not clear from the data,
theBayesianmodelaveragingapproachisabletoestimatethe
monoisotopic masses of the two overlapping peptides and to
correctly quantify their relative abundance. A slight bias for
the estimation of H2/H1 is only observed for setting 21.
Figure 10 presents, as an example, the ﬁt of the model to
the observed spectra. The ﬁgure shows that the ﬁtted spectra
correspond to the observed spectra, even for the diﬃcult
setting (setting 3).
As can be seen from Table 4, settings 1 to 20 are the
settings for which the monoisotopic mass diﬀerence of the
two overlapping peptides is at most around one Da, that
is, shift = 0 or 1. These settings can be viewed as the more
diﬃcult ones regarding their relatively small diﬀerence in
the monoisotopic mass, that is, M2 − M1. Table 5 gives a
summary of whether or not the model is able to produce
correct estimates (+ indicating correct estimation and −
indicating wrong estimation) for these settings, based on
the simulation study. Note that poor estimates are produced
whenthemassdiﬀerenceM2 − M1 ortherelativeabundance
H2/H1 is too small. In particular, Table 5 indicates that, in
general, when M2 − M1 ≥ 0.16, the model produces the
correct parameter estimates.
5.2.1. Misspeciﬁcation of the Number of Overlapping Peptides.
In order to investigate the potential inﬂuence of the mis-
speciﬁcation of the assumed number of overlapping peptides
on the parameter estimates, the simulation was repeated for
settings 10 and 26, by assuming 3 overlapping peptides (one
more than the actual number). The estimates of the ﬁrst two
peptides (ordered according to the estimated masses) were
quite similar to the ones obtained by assuming the correct
number of overlapping peptides. The abundance parameter
for the third peptide was estimated only between 0.07% and
3.66%oftheabundanceofthesecondpeptide.Thisindicates
that a third peptide may be non-existent and is very likely
incurred merely by noise. The BIC (Bayesian information
criterion) of the models with two and three overlapping
peptidesconﬁrmedthenonexistenceofthethirdoverlapping
peptides. For settings 10 and 26, the BIC for the model
withtwooverlappingpeptideswerebothsmaller(7196.5and
6567.6, resp.) than for the model with three peptides (7259.8
and 6602.1, resp.).
Hence, the two simulation studies show that our model-
ing approach is robust to the misspeciﬁcation of the number
of overlapping peptides. Moreover, the BIC for models with
diﬀerent number of overlapping peptides gives an indication
of the correct number of overlapping peptides, present in the
data.10 International Journal of Proteomics
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Figure 5: Graphical representation of settings 1–20 of simulated data sets.
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6. Discussion and Conclusions
The quantiﬁcation of the overlapping peptides is a diﬃcult
problem, because there is often a limited amount of infor-
mation available in the MS data. A possible solution is to
use prior information that could increase the information
content of the data. For this reason, in this paper, we
have considered the use of a Bayesian approach to analyze
high-resolution mass spectra with overlapping peptides. As
compared with the existing methods [1, 2], our modeling
approach allows for the incorporation of prior information,
which should lead to more precise estimates. Moreover, it
avoids a multistage analysis, which poses a diﬃculty in,
for example, estimating precision of the obtained estimates.
We have presented the model for the shape representa-
tion of a mass spectrum with overlapping peptides, ﬁtted
by using the Bayesian model averaging approach. We have
investigated the performance of the model with applications
to real-life data sets and a simulation study.
The application to the real-life data yielded, in general,
estimates corresponding to the true parameter values. The
estimates of the relative abundance exhibited a downward
bias. This may be due to incomplete labeling of peptide
molecules [9, 10]. The modeling approach was compared
with one of the existing approaches, proposed by Breen et al.
[3], which showed eﬃciency loss for the parameter of
interest. The ineﬃciency of the parameter estimates can
bring about diagnostic problems, by causing false negatives,
when applied to clinical diagnostics.
In the simulation study, when applying the modeling
approach, we observed, in general, unbiased estimation for
theparameters,witheitherclearorunclearseparationforthe
overlapping peptides in the simulated MS data. Moreover,
for the settings, for which the quantiﬁcation of the second
overlapping peptide was diﬃcult, 95% credible intervals of
theparameterestimateswerewiderandcontainedmostlythe
true values. This indicates that the width of the 95% credible
intervals correctly quantiﬁes the uncertainty of the param-
eter estimates. Two extra simulations were performed and
showed the robustness of the model to the misspeciﬁcation
of the number of overlapping peptides.
The feasibility of the quantiﬁcation of overlapping
peptides depends on the mass diﬀerence of the peptides.
When Bayesian model averaging approach is applied, it
produces unbiased estimates for the parameters related to
the overlapping peptides, when the monoisotopic mass
diﬀerence is at least 0.16Da, which is roughly a half of
the width of an isotopic peak, observed in an MALDI-
TOF mass spectrum. This indicates that the two overlapping
peptides can be correctly quantiﬁed by using the Bayesian
model averaging approach when the mass diﬀerence of
the two peptides is at least a half of the width of an
isotopic peak. A smaller mass diﬀerence, that is, less than a
half of the isotopic peak width, would suggest a complete
overlap of the peptides and would make the quantiﬁcation
infeasible.
In summary, the proposed modeling approach oﬀers two
advantages:
(i) it produces unbiased estimates for all settings that
show clear or unclear separation of the overlapping
peptides in the MS data;
(ii) the model uncertainty, measured by the 95% credible
intervals of the parameters, gives an indication of the
separability of the overlapping peptides.
Although the method is focused on the application
of singly charged MALDI-TOF mass spectrum, it can be
modiﬁed to apply also for, for example, the doubly charged
mass spectrum with the modiﬁcation of the expression for
the mean structure of the model and the prior distributions
for the corresponding parameters. Moreover, the proposed
modeling approach, assuming unknown masses (sequences)
of the overlapping peptides, can be modiﬁed for the applica-
tion,inwhichthemassesareknown.Insuchcase,themasses
of the peptides in the model can be ﬁxed with known values
and the model simpliﬁes.
It should be noted that the validity of this approach
is based on a proper-preprocessing procedure (for details
of preprocessing, refer to Vaikenborg et al. [11]). More
speciﬁcally, it assumes that a cluster of peptide peaks is
correctly found after noise ﬁltering. This implies that, if a
part of the isotopic peaks of a cluster is treated as noise
generated and discarded, the method would yield biased
estimation.
It is also worth noting that, in the analysis, the number of
overlapping peptides was assumed to be known. Usually, in
practice,thisalsoneedstobeestimated.Suchestimationmay
be diﬃcult by using a Bayesian approach since little prior
informationcanassisttheanalysis.Identifyingthenumberof
overlapping peptides can be viewed as a problem of identify-
ing the number of components of a mixture of distributions
by applying a likelihood-based testing approach, or by
performing a forward model selection approach. The latter
approach can be done by ﬁtting models with sequentially
increasing number of components, and then by selecting the
model which shows the best ﬁt, depending on, for example,
the Bayesian information criterion. The feasibility of such an
approachwasobservedfromthesimulationstudies.Tocheck
its validity in real applications may require a larger-scaled
analysis based on real-life data. This topic will be addressed
in future research.
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